C2N, a St. Louis, MO-based diagnostics company developing Precivity blood tests, raised $7.025M in funding.
The round was led by Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator.
The company intends to use the funds to develop its biomarkers and novel diagnostic technologies.
Led by CEO Dr. Joel Braunstein, C2N Diagnostics is a specialty diagnostics company providing clinical laboratory services and diagnostic solutions in the field of brain health. Its mass spectrometry-based biomarker services and products are used for clinical decision-making to improve patient care, including diagnosis and treatment monitoring, optimizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and for healthcare researchers to understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health.
C2N’s assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease.
The company has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums.
Over 30,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review. C2N has partnered with clinical diagnostic labs throughout the world to offer expanded Precivity™ testing access to providers and patients, including Unilabs across 75 countries, Grupo Fleury in Brazil and Healius Pathology in Australia for clinical use, and with Mediford Corporation in Japan for research purposes.
The company also recently announced it has entered into a non-exclusive agreement with Mayo Clinic Laboratories.
FinSMEs
26/09/2024